BridgeBio
BBOT
BridgeBio (BBOT) news
Recent news
BridgeBio announces first participant dosed in Ascend-ATTR, a phase 3B/4 study evaluating the long-term effects of acoramidis on disease regression in ATTR-CM
AInvest Wire · 5d agoBridgeBio reports second quarter 2026 financial results and corporate updates
AInvest Wire · Aug 10, 2026BridgeBio 2Q operating loss $107.1M, estimated loss $87.2M
AInvest Wire · Aug 10, 2026BridgeBio 2Q revenue $243.7M, estimate $226.5M
AInvest Wire · Aug 10, 2026Bridgebio Oncology Therapeutics Inc: JP Morgan initiates coverage with overweight rating; target price $27
JPMorgan has initiated coverage on BridgeBio Oncology Therapeutics Inc (NASDAQ:BBOT) with an overweight rating and a price target of $27.00 , according to a report dated July 8, 2026. The stock closed at $10.08 on July 8, indicating a potential upside of approximately 165% to the firm’s target…
AInvest Wire · Jul 8, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.